[HTML][HTML] COVID-19 vaccine development: milestones, lessons and prospects
M Li, H Wang, L Tian, Z Pang, Q Yang… - Signal transduction and …, 2022 - nature.com
With the constantly mutating of SARS-CoV-2 and the emergence of Variants of Concern
(VOC), the implementation of vaccination is critically important. Existing SARS-CoV-2 …
(VOC), the implementation of vaccination is critically important. Existing SARS-CoV-2 …
[HTML][HTML] T cell responses to SARS-CoV-2
A large body of evidence generated in the last two and a half years addresses the roles of T
cells in SARS-CoV-2 infection and following vaccination. Infection or vaccination induces …
cells in SARS-CoV-2 infection and following vaccination. Infection or vaccination induces …
[HTML][HTML] Immunological mechanisms of vaccine-induced protection against COVID-19 in humans
M Sadarangani, A Marchant… - Nature Reviews …, 2021 - nature.com
Most COVID-19 vaccines are designed to elicit immune responses, ideally neutralizing
antibodies (NAbs), against the SARS-CoV-2 spike protein. Several vaccines, including …
antibodies (NAbs), against the SARS-CoV-2 spike protein. Several vaccines, including …
[HTML][HTML] Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2
Although two-dose mRNA vaccination provides excellent protection against SARS-CoV-2,
there is little information about vaccine efficacy against variants of concern (VOC) in …
there is little information about vaccine efficacy against variants of concern (VOC) in …
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a …
X Liu, RH Shaw, ASV Stuart, M Greenland, PK Aley… - The Lancet, 2021 - thelancet.com
Background Use of heterologous prime-boost COVID-19 vaccine schedules could facilitate
mass COVID-19 immunisation. However, we have previously reported that heterologous …
mass COVID-19 immunisation. However, we have previously reported that heterologous …
[HTML][HTML] Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis
A Choi, M Koch, K Wu, L Chu, LZ Ma, A Hill, N Nunna… - Nature medicine, 2021 - nature.com
The emergence of SARS-CoV-2 variants of concern (VOCs) and variants of interest (VOIs)
with decreased susceptibility to neutralization has generated interest in assessments of …
with decreased susceptibility to neutralization has generated interest in assessments of …
[HTML][HTML] The current landscape of nucleic acid therapeutics
The increasing number of approved nucleic acid therapeutics demonstrates the potential to
treat diseases by targeting their genetic blueprints in vivo. Conventional treatments …
treat diseases by targeting their genetic blueprints in vivo. Conventional treatments …
[HTML][HTML] Lipid nanoparticles for mRNA delivery
Messenger RNA (mRNA) has emerged as a new category of therapeutic agent to prevent
and treat various diseases. To function in vivo, mRNA requires safe, effective and stable …
and treat various diseases. To function in vivo, mRNA requires safe, effective and stable …
[HTML][HTML] Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents
K Ali, G Berman, H Zhou, W Deng… - … England Journal of …, 2021 - Mass Medical Soc
Background The incidence of coronavirus disease 2019 (Covid-19) among adolescents
between 12 and 17 years of age was approximately 900 per 100,000 population from April 1 …
between 12 and 17 years of age was approximately 900 per 100,000 population from April 1 …
Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants
A Pegu, SE O'Connell, SD Schmidt, S O'Dell… - Science, 2021 - science.org
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutations may diminish
vaccine-induced protective immune responses, particularly as antibody titers wane over …
vaccine-induced protective immune responses, particularly as antibody titers wane over …